Evidence map›Paper›PMID 40941653›Full record

ArticleDiagnostics (Basel, Switzerland)2025

Tumor Cell Proportion Assessment in Advanced Non-Squamous Non-Small Cell Lung Cancer Tissue Samples in Real-World Settings in Japan: The ASTRAL Study.

Kanako C Hatanaka, Kazumi Nishino, Tomoyuki Yokose, Hiroshi Tanaka, Noriko Motoi, Kenichi Taguchi, Yoichi Tamai, Takehiro Hirai, Yutaka Yabuki, Yutaka Hatanaka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kanako C HatanakaCenter for Development of Advanced Diagnostics, Hokkaido University Hospital, Sapporo 060-8648, Japan.
Kazumi NishinoDepartment of Thoracic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.ORCID 0000-0003-2000-7472
Tomoyuki YokoseDepartment of Pathology, Odawara Municipal Hospital, Odawara 250-8558, Japan.ORCID 0000-0002-9403-9592
Hiroshi TanakaDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata 951-8566, Japan.
Noriko MotoiDepartment of Pathology, Saitama Cancer Center, Saitama 362-0806, Japan.ORCID 0000-0001-7098-3311
Kenichi TaguchiDepartment of Pathology, National Hospital Organization, Kyushu Cancer Center, Fukuoka 811-1395, Japan.ORCID 0000-0002-6753-2795
Yoichi TamaiAstraZeneca K.K., Osaka 530-0011, Japan.
Takehiro HiraiAstraZeneca K.K., Osaka 530-0011, Japan.ORCID 0000-0002-0214-1056
Yutaka YabukiAstraZeneca K.K., Osaka 530-0011, Japan.ORCID 0000-0001-9107-6227
Yutaka HatanakaCenter for Development of Advanced Diagnostics, Hokkaido University Hospital, Sapporo 060-8648, Japan.ORCID 0000-0003-3128-1477

Funding

AstraZeneca K.K. Not applicable
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

advanced non-squamous non-small cell lung cancerartificial intelligence algorithmbiomarker testingintraclass correlation coefficienttumor cell proportion assessment

Identifiers

PMID40941653
PMCPMC12428467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.